Medtronic will dominate Japanese DCB market over next five years, says GlobalData
Following the full commercial launch of the IN.PACT Admiral Drug-Coated Balloon (DCB), for the treatment of peripheral artery disease (PAD) in the upper leg - specifically, in the thigh (superficial femoral arteries (SFA)) and behind the knee (popliteal arteries), in Japan on 15 August 2018 by Dublin-based medical device company Medtronic,
Sheryl Tang, Medical Device Analyst at leading data and analytics company GlobalData says:
“IN.PACT Admiral DCB was first approved by Japan Pharmaceuticals and Medical Devices Agency (PMDA) in September 2017, shortly after the approval of CR Bard’s Lutonix DCB in August 2017. Prior to 2017, there were no DCB’s commercially available in Japan. The Lutonix DCB will likely be commercially available shortly after the release of the IN.PACT Admiral.
“Over the next five years, Bard will be able to make its presence felt and account for a market share of 35%, however, Medtronic will still dominate the market with 65% share given its larger medical devices portfolio and presence within the country.”
For more information
To gain access to our latest press releases: GlobalData Media Centre